Pharmaceuticals News and Research

RSS

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated a new Phase III trial designed to evaluate the efficacy, tolerability and safety of pimavanserin as a treatment for patients with Parkinson's disease psychosis (PDP).

30 Jul 2010

Anadys second-quarter net loss decreases to $3.0 million

Anadys Pharmaceuticals, Inc., a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its financial results and program highlights for the second quarter ended June 30, 2010.

29 Jul 2010

Isis Pharmaceuticals receives $5M payment from GSK for dug development

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation as a development candidate of a drug to treat an undisclosed rare and serious disease. Isis will develop the drug to Phase 2 proof-of-concept, at which time GSK has the option to license it.

29 Jul 2010

Talecris Biotherapeutics Holdings second-quarter 2010 net revenue increases 7.3% to $402.8 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three and six months ended June 30, 2010 and filed its 2010 Form 10-Q with the U.S. Securities and Exchange Commission.

29 Jul 2010

ZOLL Medical receives PMDA approval to distribute AED Plus, AED Pro in Japan

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it has been granted approval by the Japanese Pharmaceutical and Medical Devices Agency to import and distribute the AED Plus and AED Pro in Japan.

29 Jul 2010

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended June 30, 2010 was $91.6 million, up 47% from $62.3 million for the same partner companies in the same period of 2009. For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45% from $121.8 million for the same partner companies for the same period of 2009.

29 Jul 2010

AVEO second-quarter total revenues increase to $15.6 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.

29 Jul 2010

Covidien third-quarter 2010 net sales increase 2% to $2.56 billion

Covidien plc today reported results for the third quarter of fiscal 2010 (April - June 2010). Third-quarter net sales of $2.56 billion increased 2% from the $2.52 billion reported a year ago, with foreign exchange rate movement having no impact on the quarterly sales growth rate.

29 Jul 2010

Aptuit announces strategic partnership Siena Biotech

Aptuit, Inc., and Siena Biotech S.p.A., today announced a strategic partnership in which Siena Biotech will take a minority stake in Aptuit's Italian operations in Verona, Italy, and Aptuit will become a provider of choice for Siena Biotech's development pipeline. Under the agreement Aptuit and Siena Biotech will work collaboratively on the development of Siena Biotech's pipeline of compounds, focused in three key therapeutic areas, including Alzheimer's disease, Huntington's disease and oncology.

29 Jul 2010

FDLI's monograph describes impact of manufacturer's commercial pricing decisions on product pricing

In FDLI's latest monograph, Selling Pharmaceuticals and Biologics to the Federal Government: Federal Supply Schedule and Federal Pricing Requirements, Joy Sturm, Allison Pugsley and Stephen A. Smyers of Hogan Lovells US LLP detail how pharmaceutical and biologics manufacturers can deal effectively with government contracting requirements and price calculation requirements.

29 Jul 2010

AHF accuses Bristol-Myers Squibb of lying about cooperation with HIV/AIDS community

Today AIDS Healthcare Foundation (AHF) responded to a statement placed by drug giant Bristol-Myers Squibb (BMS) on its website defending its record on AIDS drug pricing and accessibility.

29 Jul 2010

BD third-quarter revenues increase 3.2% to $1.878 billion

BD, a leading global medical technology company, today reported quarterly revenues of $1.878 billion for the third fiscal quarter ended June 30, 2010, representing an increase of 3.2 percent from the prior-year period, or 3.9 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 29 Jul 2010

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.

29 Jul 2010

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Angiotech Pharmaceuticals, Inc. and partner Athersys, Inc. announced positive results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction, more commonly referred to as a heart attack.

29 Jul 2010

Clarient second-quarter net revenue increases 21% to $28.7 million

Clarient, Inc., a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the second quarter ended June 30, 2010. Second quarter 2010 net revenue was $28.7 million, a 21 percent increase over the $23.7 million net revenue in the 2009 second quarter and a sequential increase of nearly eight percent over the $26.6 million in the first quarter of 2010.

29 Jul 2010

Eli Lilly disagrees with U.S. Court of Appeals ruling on Gemzar method-of-use patent

Eli Lilly and Company today announced that the U.S. Court of Appeals for the Federal Circuit has upheld a prior ruling by the U.S. District Court for the Eastern District of Michigan that Gemzar's method-of-use patent is invalid.

29 Jul 2010

Partnership for Safe Medicines to convene counterfeit drug conference

The Partnership for Safe Medicines (PSM), a group of nonprofit organizations and individuals dedicated to protecting consumers from counterfeit drugs, today announced that it will convene leaders from academia, government and industry in an inaugural conference to be held October 8th at the National Press Club in Washington, D.C.

29 Jul 2010

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.

29 Jul 2010

PCMA issues statement on a provision in the U.S. Senate's small business legislation

Pharmaceutical Care Management Association President and CEO Mark Merritt issued the following statement today on a provision in the U.S. Senate's small business legislation that would require the Department of Health and Human Services to work with outside companies to target fraud, waste, and abuse in states across the country.

29 Jul 2010

Oxford Finance leads $30 million credit facility provided to Cadence for launch of OFIRMEV

Oxford Finance Corporation, a subsidiary of Sumitomo Corporation, today announced that it was the lead lender for a $30 million credit facility provided to Cadence Pharmaceuticals. Silicon Valley Bank and GE Financial Services, Inc. also participated in the loan agreement. This infusion of capital will support the company's potential launch of their investigational product candidate, OFIRMEV™, an intravenous formulation of acetaminophen that is currently marketed in Europe for the treatment of acute pain and fever.

29 Jul 2010

Pharmaceuticals News and Research

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

Anadys second-quarter net loss decreases to $3.0 million

Isis Pharmaceuticals receives $5M payment from GSK for dug development

Talecris Biotherapeutics Holdings second-quarter 2010 net revenue increases 7.3% to $402.8 million

ZOLL Medical receives PMDA approval to distribute AED Plus, AED Pro in Japan

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

AVEO second-quarter total revenues increase to $15.6 million

Covidien third-quarter 2010 net sales increase 2% to $2.56 billion

Aptuit announces strategic partnership Siena Biotech

FDLI's monograph describes impact of manufacturer's commercial pricing decisions on product pricing

AHF accuses Bristol-Myers Squibb of lying about cooperation with HIV/AIDS community

BD third-quarter revenues increase 3.2% to $1.878 billion

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Clarient second-quarter net revenue increases 21% to $28.7 million

Eli Lilly disagrees with U.S. Court of Appeals ruling on Gemzar method-of-use patent

Partnership for Safe Medicines to convene counterfeit drug conference

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

PCMA issues statement on a provision in the U.S. Senate's small business legislation

Oxford Finance leads $30 million credit facility provided to Cadence for launch of OFIRMEV

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence